Fusion proteins and use thereof for preparing vaccines

An immunogenic fusion protein comprising at least two peptides:

• a) on the C-terminal side, a first peptide which consists of:
• an amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, wherein the sequence of the protein S is chosen from the group consisting of SEQ ID NO:
• 1 and 2, and the sequence of the protein M is chosen from the group consisting of SEQ ID NO:
• 3 and 4, or
• an amino acid sequence with a percent identity of at least 95% with said amino acid sequence of the protein S or the protein M, provided that said amino acid sequence maintains the ability to form subviral, non-infectious particles and/or immunogenic properties against the HBV virus, or, and
• b) on the N-terminal side, a second peptide which consists of:
• a sequence of amino acids comprising at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate, or
• an amino acid sequence with a percent identity of at least 95% with said amino acid sequence of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate, provided that said amino acid sequence maintains the ability to form subviral, non-infectious particles and/or immunogenic properties against the Zika virus, said protein of a Zika virus isolate being chosen from among the envelope protein E represented by SEQ ID NO. 15 or a fusion peptide comprising the envelope protein E and the protein prM represented by SEQ ID NO. 50.